News | January 24, 2026
Jagsonpal Pharmaceuticals posts Q3 FY26 profit at Rs. 10.95 Cr
Jagsonpal Pharmaceuticals has reported total income of Rs. 75.92 crore during the period ended December 31, 2025
Jagsonpal Pharmaceuticals has reported total income of Rs. 75.92 crore during the period ended December 31, 2025
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The partnership also sets the stage for broader collaboration on rare disease treatments
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
Subscribe To Our Newsletter & Stay Updated
